CYT003-QbG10

DRUG3 trials

Sponsors

Cytos Biotechnology AG

Conditions

Allergic Bronchial AsthmaAllergiesPerennial Allergy to House Dust Mite and/or CatRhinoconjunctivitis

Phase 2

Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

CompletedNCT00575003

Cytos Biotechnology AGPerennial Allergy to House Dust Mite and/or Cat

Start: 2007-12-31End: 2009-03-31Target: 64Updated: 2009-04-27

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

CompletedNCT00800332

Cytos Biotechnology AGAllergies, Rhinoconjunctivitis

Start: 2008-11-30End: 2010-11-30Target: 300Updated: 2010-11-15

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

CompletedNCT00890734

Cytos Biotechnology AGAllergic Bronchial Asthma

Start: 2009-04-30End: 2010-11-30Updated: 2012-02-13

Related Papers

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

2013-02-04125 citations

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.

2011-06-14103 citations